IP Library › Granted Patent US 12,403,113
Granted Patent B2
US 12,403,113 · App. 17/594,629 · Granted Sep 2, 2025

Composition containing creatine fatty ester for use in medicine

Inventors: Aloïse Mabondzo (Paris, FR); Gabriela Ullio-Gamboa (GIF s/ Yvette, FR); Anne-Cécile Guyot (Rueilmalmaison, FR); Sophie Dezard (Forges les Bains, FR); Frédéric Taran (GIF s/ Yvette, FR); Henri Benech (Paris, FR); Olivier Loreau (St Michel s/ Orge, FR)
Assignee: COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
A61K31/201A61K31/202A61K45/06A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,403,113
App. No.
17/594,629
Granted
Sep 2, 2025
Kind
B2
Abstract

A composition comprising at least one creatine fatty ester or salt thereof, at least one omega 3 fatty acid or salt thereof and at least one glyceride for use in medicine, the composition being free of non ionic surfactants and in particular said composition for use in treating the brain creatine transporter deficiency disease.

Claims (15)

1. A composition for use in medicine, said composition comprising at least one creatine fatty ester or salt thereof in an amount of 0.01% to 6% by weight based on the total weight of the composition, at least one omega 3 fatty acid or salt thereof in an amount of 15% to 35% by weight based on the total weight of the composition and at least one glyceride in an amount of 60% to 85% by weight based on the total weight of the composition, said composition being free of non ionic surfactants.

2. The composition according to claim 1 , wherein said creatine fatty ester is represented by the formula (I):

(NH 2 )—C(NH)—N(CH 3 )—CH 2 —COOR  (I)

in which R represents an alkyl radical with 4 to 30 carbon atoms, an alkenyl radical with 4 to 30 carbon atoms or an aryl radical with 6 to 30 carbon atoms.

3. The composition according to claim 1 , wherein said creatine fatty ester or salt thereof is dodecyl creatine ester or hydrochloride salt of dodecyl creatine ester.

4. The composition according to claim 1 , wherein said at least one creatine fatty ester or salt thereof is present in an amount of 0.02% to 5.5% by weight based on the total weight of the composition.

5. The composition according to claim 1 , wherein said at least one omega-3 fatty ester or salt thereof is docosahexaenoic acid (DHA).

6. The composition according to claim 1 , wherein said at least one omega-3 fatty ester or a salt thereof is present in an amount of 20% to 30% by weight based on the total weight of the composition.

7. The composition according to claim 1 , wherein said at least one glyceride is a mixture of mono-, di- and triglycerides of linoleic (C 18:2 ) and oleic (C 18:1 ) acids.

8. The composition according to claim 1 , wherein said at least one glyceride is present in an amount of 70% to 80% by weight based on the total weight of the composition.

9. The composition according to claim 1 , wherein said composition is prepared by a method comprising a step consisting in mixing at least one creatine fatty ester or salt thereof, at least one omega 3 fatty acid or salt thereof and at least one glyceride.

10. The composition according to claim 1 , wherein said composition is for use in the treating or the preventing of at least one disease, disorder or condition selected in the group consisting of a neuromuscular disorder, hypoxia, an ischemic brain disease, an heart disease, a muscular dystrophy, a skin disorder, a neurodegenerative disease, leukodystrophy, a psychiatric disorder, and inflammation and wherein said composition is suitable for nasal administration.

11. The composition according to claim 1 , wherein said composition is for use in treating brain creatine transporter deficiency disease and wherein said composition is suitable for nasal administration.

12. The composition according to claim 1 , wherein said composition is suitable for nasal administration.

13. The composition according to claim 1 , wherein the composition is for use in treating or preventing an ageing-related condition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2022
From: MABONDZO, ALOÏSE; ULLIO-GAMBOA, GABRIELA; GUYOT, ANNE-CÉCILE; DEZARD, SOPHIE; TARAN, FRÉDÉRIC; BENECH, HENRI; LOREAU, OLIVIER
To: COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
Reel/Frame 060116/0553 →
Priority Claims (1)
EP 19305548 · Apr 30, 2019 · regional
Continuity (1)
Related Publication 20220211651A1 · Jul 7, 2022
References Cited (33)
US 20020049253A1 · Kaddurah-Daouk · 2002 [cited by applicant]
US 20030212130A1 · Miller et al. · 2003 [cited by applicant]
US 20150238453A1 · Owoc · 2015 [cited by applicant]
US 20210128467A1 · Mabondzo · 2021 [cited by applicant]
EP 0589843B1 · 2011 [cited by applicant]
EP 2692719B1 · 2016 [cited by applicant]
WO 0222135A1 · 2002 [cited by applicant]
WO WO2015120299A1 · 2015 [cited by examiner]
Trotier-Faurion et al., Nanomedecine, 2015, 10(2), 185-191. (Year: 2015). [cited by examiner]
Trotier-Faurion, PHD Thesis, 2013, Univ. Paris-Sud. (Year: 2013). [cited by examiner]
Stockler, Sylvia et al, “Cerebral creatine deficiency syndromes. Clinical aspects, treatment and pathophysiology”, Subcell. Biochem., 2007, vol. 46, pp. 149-166. [cited by applicant]
Green, Douglas R et al. “Mitochondria and the autophagy-inflammation-cell death axis in organismal aging” Science. Aug. 26, 2011; vol. 333, 1109-1112. [cited by applicant]
Van De Kamp, Jiddeke M. et al “X-linked creatine transporter deficiency: clinical aspects and pathophysiology”, J Inherit Metab Dis., 2014, vol. 37, pp. 715-733. [cited by applicant]
Kurosawa, Yuko et al, “Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency”, The Journal of CLinical Invenstigation, 2012, vol. 122(8), pp. 2837-2846. [cited by applicant]
Trotier-Faurion, Alexandra et al, Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising Nanomedicine, 2015 J. Med. Chem., vol. 56, pp. 5173-5181. [cited by applicant]
Trotier-Faurion, Alexandra et al, “Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency”, Nanomedicine, 2013, vol. 10, pp. 185-191. [cited by applicant]
Banerjee, Bidisha et al, “Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS Study”, 2010, Ma… [cited by applicant]
Balestrino, Maurizio et al, “Potential of creatine or phosphocreatine supplementation in cerebrovascular disease and in ischemic heart disease”, 2016, Amino Acids, vol. 48, pp. 1955-1967. [cited by applicant]
Royes, Luiz Fernando Freire et al., 2016, “The effects of creatine supplementation and physical exercise on traumatic brain injury”, Mini Review in Medicinal Chemistry, vol. 16, pp. 29-39. [cited by applicant]
Brewer, Gregory et al. “Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons”, Journal of Neurochemistry, 2000, vol. 74, pp. 1968-1978. [cited by applicant]
Lesman, M. et al, “Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat”, Brain Res, 2006, vol. 1114, pp. 187-194. [cited by applicant]
Chaturvedi, Rajnish et al. “Mitochondrial approaches for neuroprotection”, Annals od the New York Academy of Sciences, 2008, vol. 1147, pp. 395-412. [cited by applicant]
Abou-Sleiman, Patrick M. et al, “Expanding insights of mitochondrial dysfunction in Parkinson's disease”, Nature Reviews/Neuroscience, Mar. 2006, vol. 7, pp. 207-219. [cited by applicant]
Matthews, Russell T. et al, “Creatine and cyclocreatine attenuate MPTP neurotoxicity”, Exp Neurol, vJan. 19, vol. 157, pp. 142-149. [cited by applicant]
Adhihetty, Peter J. et al, “Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases”, Neuromolecular Med, 2008, vol. 10, pp. 275-290. [cited by applicant]
Hersch, S.M. et al, 2006, “Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG”, Neurology, vol. 66, pp. 250-252. [cited by applicant]
Allen, Patricia J., “Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?”, Neuroscience Biobehavioral Reviews, v2012, ol. 36, pp. 1442-1462. [cited by applicant]
Isper, Jonathan C. et al, “1H-MRS in autism spectrum disorders: a systematic meta-analysis”, Metab Brain Dis, v2012, vol. 27, pp. 275-287. [cited by applicant]
Hoerst, Mareen et al, 2010, “Metabolic alterations in the amygdala in borderline personality disorder: a proton magnetic resonance spectroscopy study”, Biol Psychiatry, vol. 67, pp. 399-405. [cited by applicant]
Bender, A. et al, 2008, “Creatine improves health and survival of mice”, Neurobiology of Aging, vol. 29, pp. 1404-1411. [cited by applicant]
Skelton, Matthew R.et al, “Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency”, PLoS One, Jan. 2011, vol. 6, e16187. [cited by applicant]
Search Report for European application No. EP19305548 dated Oct. 23, 2019. [cited by applicant]
International Search Report and Written Opinion for application No. PCT/EP2020/061824 dated Jul. 13, 2020. [cited by applicant]